TheRaCil - TheRaCil – Advancing Therapies for Pediatric Renal Ciliopathies

  • Join us
  • Project
    • Workplan
  • Consortium
  • News and Publications
  • Events
  • Contact
HomeNews and PublicationsPublications

Publications

posted on June 12, 2025 NewsPublications

A risk score to predict kidney survival in patients with autosomal recessive polycystic kidney disease at the age of two months

Burgmaier et al, Kidney International, May 2025.

posted on June 12, 2025 NewsPublications

Urinary peptide signature distinguishes autosomal recessive polycystic kidney disease from other causes of chronic kidney disease

Burgmaier et al, Clinical Kidney Journal, May 2025.

posted on June 12, 2025 NewsPublications

Polycystic Kidney Disease in Children: The Current Status and the Next Horizon

Cadnapaphornchai et al, American Journal of Kidney Diseases, March 18, 2025.

posted on June 12, 2025 NewsPublications

Comparing representations of long clinical texts for the task of patient note-identification

Alsaidi et al, CL4Health@NAACL 2025, May 2025.

posted on May 14, 2025 NewsPublications

Prostaglandin Analogs and Eupatilin as Treatments for Nephronophthisis

Tata et al, Kidney International Reports, Articles in Press, May 1, 2025.

posted on November 7, 2024 NewsPublications

Urinary Dickkopf-3 Reflects Disease Severity and Predicts Short-Term Kidney Function Decline in Renal Ciliopathies

Dahmer-Heath et al, Kidney International Reports, January 2025.

  • Join us
  • Project
    • Workplan
  • Consortium
  • News and Publications
  • Events
  • Contact

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101080717

  • Therapies for Renal Ciliopathies
  • Join us
  • Workplan
  • Consortium
  • Contact

  • Privacy policy
  • Legal notices and credits
Tous droits réservés © TheRaCil 2025
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkNoPrivacy policy